ONCY Stock Forecast & Price Target

Oncolytics Biotech is attractive because its lead asset pelareorep has multiple FDA-aligned shots on goal, with REO 033 advancing toward pivotal development in 2L RAS-mutated MSS mCRC and a randomized SCAC trial that could support both accelerated and full approval within one study. The company’s data package is improving on both clinical and mechanistic fronts, including reported 33% ORR, 19.5-month duration of response, 16.6-month PFS and 27-month OS versus historical benchmarks, while translational work at ASCO 2026 and AACR 2026 reinforced the immune-priming rationale. Financially, June 30 cash and cash equivalents were $4.1 million, but recent ATM financing of about $6.8 million and a focused GI-cancer strategy improve near-term execution, especially if REO 033 enrollment and year-end 2026 updates confirm the thesis.

Oncolytics Biotech is facing a weakened investment case because the CPI supply and funding partner has become the gating item for both SCAC and mPDAC, with the SCAC pivotal protocol still being finalized and initiation now partner-contingent rather than on the prior late-3Q26 path. The company also lost a near-term catalyst as GOBLET Cohort 4 final analysis is now open-ended despite complete enrollment, while management’s focus has shifted toward REO 033 in mCRC, underscoring capital constraints rather than a clean clinical setback. Financially, the outlook is pressured by modeled annual gross equity raises of $50M-$100M from 2026E-2028E, which could dilute shareholders, and by reduced probabilities of success and lower revenue expectations across pelareorep programs.